New-onset diabetes is one of the most common complications after cardiac surgery, which can lead to increased mortality and rejection events. Early detection and active management of new-onset diabetes after cardiac surgery are important contents to promote the clinical benefits of patients undergoing cardiac surgery. Therefore, this paper reviews the risk factors for new-onset diabetes after two important types of cardiac surgery coronary revascularization and heart transplantation, in order to provide ref-erences for the early and comprehensive management of new-onset diabetes after cardiac surgery.

1..Leavitt BJ, Sheppard L, Maloney C, et al. Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery[J]. Circulation, 2004, 110(11 Suppl 1): II41-II44. DOI: 10.1161/01.CIR.0000138197.07051.e7.

2..Chun KH, Im E, Kim BK, et al. Incidence, predictors, and clinical outcomes of new-onset diabetes mellitus after percutaneous coronary intervention with drug-eluting stent[J]. J Korean Med Sci, 2017, 32(10): 1603-1609. DOI: 10.3346/jkms.2017.32.10.1603.

3..Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3): 172-188. DOI: 10.1038/s41574-018-0137-7.

4..Vest AR, Cherikh WS, Noreen SM, et al. New-onset diabetes mellitus after adult heart transplantation and the risk of renal dysfunction or mortality[J]. Transplantation, 2022, 106(1): 178-187. DOI: 10.1097/TP. 0000000000003647.

5..Kim HJ, Jung SH, Kim JJ, et al. New-onset diabetes mellitus after heart transplantation - incidence, risk factors and impact on clinical outcome[J]. Circ J, 2017, 81(6): 806-814. DOI: 10.1253/circj.CJ-16-0963.

6..张红强. 心脏移植术后新生糖尿病危险因素分析及对长期预后的影响[D]. 复旦大学, 2008. [Zhang HQ. Study on risk factors for new onset diabetes mellitus post orthotopic heart transplant (PTDM) and the rela-tionship between PTDM and long-term survival[D]. Fudan University, 2008.]

7..Ye X, Kuo HT, Sampaio MS, et al. Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients[J]. Transplantation, 2010, 89(12): 1526-1532. DOI: 10.1097/TP.0b013e3181dd6bd9.

8..Zielińska K, Kukulski L, Wróbel M, et al. Prevalence and risk factors of new-onset diabetes after trans-plantation (Nodat)[J]. Ann Transplant, 2020, 25: e926556. DOI: 10.12659/AOT.926556.

9..张红强, 王春生, 陈昊, 等. 心脏移植术后新生糖尿病的危险因素分析[J]. 中华器官移植杂志, 2009, (11): 645-649. [Zhang HQ, Wang CS, Chen H, et al. Study on risk factors for new onset diabetes mellitus post ortho-topic heart transplant (PTDM) and the relationship between PTDM and long-term survival[J]. Chinese Journal of Organ Transplantation, 2009, (11): 645-649.] DOI: 10.3760/cma.j.issn.0254-1785.2009.11.001.

10..刘锐芮, 吴晨曦, 高静, 等. 心脏移植术后患者新发糖尿病危险因素的Meta分析[J]. 护理学杂志, 2021, (19): 35-38. [Liu RR, Wu CX, Gao J, et al. Risk factors of new-onset diabetes mellitus after heart transplantation: a Meta-analysis[J]. Journal of Nursing Science, 2021, (19): 35-38.] DOI: 10.3870/j.issn.1001-4152.2021.19.035.

11..Munshi VN, Saghafian S, Cook CB, et al. Incidence, risk factors, and trends for postheart transplanta-tion diabetes mellitus[J]. Am J Cardiol, 2020, 125(3): 436-440. DOI: 10.1016/j.amjcard.2019.10.054.

12..Wang R, Zhang Y, Fan J, et al. Risk factors for new-onset diabetes mellitus after heart transplantation: a nomogram approach[J]. Transplant Proc, 2022, 54(3): 762-768. DOI: 10.1016/j.transproceed.2022.01.030.

13..张敏, 蔡杰, 张菁, 等. 他克莫司血药浓度及相关基因多态性与心脏移植术后新发糖尿病的相关性[J]. 医药导报, 2020, (10): 1413-1418. [Zhang M, Cai J, Zhang J, et al. Associations of tacrolimus trough concentrations and genetic polymorphisms with new onset diabetes after heart transplantation[J]. Herald of Medi-cine, 2020, (10): 1413-1418.] DOI: 10.3870 / j.issn.1004-0781.2020.10.018.

14..邹诗施, 李宁, 耿庆. 他克莫司相关移植术后糖尿病发生机制的研究进展[J]. 中华器官移植杂志, 2022, (7): 434-438. [Zou SS, Li N, Geng Q. Research progress in the pathogenesis of tacrolimus-related diabetes after transplantation[J]. Chinese Journal of Organ Transplantation, 2022, (7): 434-438.] DOI: 10.3760/cma.j.cn421203-20220301-00030.

15..Heegaard B, Nelson LM, Gustafsson F. Steroid withdrawal after heart transplantation in adults[J]. Transpl Int, 2021, 34(12): 2469-2482. DOI: 10.1111/tri.14142.

16..章保勇, 胡盛寿, 黄洁, 等. 心脏移植受者移植后新发糖尿病的危险因素分析[J]. 中华器官移植杂志, 2014, 35(4): 221-224. [Zhang BY, Hu ST, Huang J, et al. Incidence and risk factors of post-transplant diabetes mellitus in heart recipients[J]. Chinese Journal of Organ Transplantation, 2014, 35(4): 221-224.] DOI: 10.3760/cma.j.issn.0254-1785.2014.04.007.

17..Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors[J]. Transplantation, 1991, 51(2): 343-347. DOI: 10.1097/00007890-199102000-00014.

18..张敏. 心脏移植术后新发糖尿病的危险因素分析及其风险预测模型建立[D]. 重庆医科大学, 2020. [Zhang M. De-termination of risk factors and establishment of risk prediction models for new onset diabetes after heart transplantation[D]. Chongqing Medical university, 2020.]

19..Peled Y, Ram E, Lavee J, et al. Hypomagnesemia is associated with new-onset diabetes mellitus fol-lowing heart transplantation[J]. Cardiovasc Diabetol, 2019, 18(1): 132. DOI: 10.1186/s12933-019-0939-5.

20..Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with in-creased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation[J]. Diabetologia, 2004, 47(9): 1550-1556. DOI: 10.1007/s00125-004-1499-z.

21..Hjelmesaeth J, Müller F, Jenssen T, et al. Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage[J]. Nephrol Dial Transplant, 2005, 20(11): 2311-2315. DOI: 10.1093/ndt/gfi033.

22..Kieboom BCT, Ligthart S, Dehghan A, et al. Serum magnesium and the risk of prediabetes: a popula-tion-based cohort study[J]. Diabetologia, 2017, 60(5): 843-853. DOI: 10.1007/s00125-017-4224-4.

23..Barbagallo M, Dominguez LJ, Galioto A, et al. Role of magnesium in insulin action, diabetes and car-dio-metabolic syndrome X[J]. Mol Aspects Med, 2003, 24(1-3): 39-52. DOI: 10.1016/s0098-2997(02)00090-0.

24..Iannino N, Nasri A, Räkel A, et al. Temporal changes on the risks and complications of posttransplan-tion diabetes mellitus following cardiac transplantation[J]. J Transplant, 2018, 2018: 9205083. DOI: 10.1155/2018/9205083.

25..Czer LSC, Wong AV, Soukiasian H, et al. Prolonged cold ischemic times and less donor-recipient his-tocompatibility accelerate graft vascular disease[J]. Transplant Proc, 2011, 43(10): 3863-3868. DOI: 10.1016/j.transproceed. 2011.09.040.

26..Schwartz GG, Leiter LA, Ballantyne CM, et al. Dalcetrapib reduces risk of new-onset diabetes in pa-tients with coronary heart disease[J]. Diabetes Care, 2020, 43(5): 1077-1084. DOI: 10.2337/dc19-2204.

27..Choi JY, Choi CU, Choi BG, et al. New onset diabetes mellitus and cardiovascular events in korean pa-tients with acute myocardial infarction receiving high-intensity statins[J]. BMC Pharmacol Toxicol, 2021, 22(1): 11. DOI: 10.1186/s40360-021-00476-z.

28..Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospec-tive meta-analysis of data from 90,056 participants in 14 randomised trials of statins[J]. Lancet, 2005, 366(9493): 1267-1278. DOI: 10.1016/S0140-6736(05) 67394-1.

29..宁小方, 姬富才. 瑞舒伐他汀对冠心病患者经皮冠状动脉介入治疗术后血管内皮功能及预后的影响[J]. 中国基层医药, 2016, 23(24): 3688-3691. [Ning XF, Ji FC. Effect of atorvastatin on vascular endothelial function and prognosis of patients with coronary heart disease after percutaneous coronary intervention[J]. Chi-nese Journal of Primary Medicine and Pharmacy, 2016, 23(24): 3688-3691.] DOI: 10.3760/cma.j.issn.1008-6706.2016.24.003.

30..Rahhal A, Khir F, Orabi B, et al. A comparative study of high-intensity rosuvastatin versus atorvastatin therapy post-acute coronary syndrome using real-world data[J]. Curr Probl Cardiol, 2022, 47(7): 100956. DOI: 10.1016/j.cpcardiol.2021.100956.

31..Carmena R, Betteridge DJ. Diabetogenic action of statins: mechanisms[J]. Curr Atheroscler Rep, 2019, 21(6): 23. DOI: 10.1007/s11883-019-0780-z.

32..Rahal AJ, ElMallah AI, Poushuju RJ, et al. Do statins really cause diabetes? a meta-analysis of major randomized controlled clinical trials[J]. Saudi Med J, 2016, 37(10): 1051-1060. DOI: 10.15537/smj.2016.10.16078.

33..Danaei G, García Rodríguez LA, Fernandez Cantero O, et al. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival[J]. Diabetes Care, 2013, 36(5): 1236-1240. DOI: 10.2337/dc12-1756.

34..Lin ZF, Wang CY, Shen LJ, et al. Statin use and the risk for incident diabetes mellitus in patients with acute coronary syndrome after percutaneous coronary intervention: a population-based retrospective cohort study in Taiwan[J]. Can J Diabetes, 2016, 40(3): 264-269. DOI: 10.1016/j.jcjd.2015.12.006.

35..Choi JY, Choi CU, Hwang SY, et al. Effect of pitavastatin compared with atorvastatin androsuvastatin on new-onset diabetes mellitus in patientswith acute myocardial infarction[J]. Am J Cardiol, 2018, 122(6): 922-928. DOI: 10.1016/j.amjcard.2018.06.017.

36..Cho KH, Jeong MH. Clinical benefit of statins in korean patients with acute myocardial infarction: ex-perience of the korea acute myocardial infarction registry[J]. J Lipid Atheroscler, 2020, 9(3): 362-379. DOI: 10.12997/jla.2020.9.3.362.

37..Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis[J]. JAMA, 2011, 305(24): 2556-2564. DOI: 10.1001/jama.2011.860.

38..Ko DT, Wijeysundera HC, Jackevicius CA, et al. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins[J]. Circ Car-diovasc Qual Outcomes, 2013, 6(3): 315-322. DOI: 10.1161/CIRCOUTCOMES. 111.000015.

39..Jeong HS, Hong SJ, Son S, et al. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up[J].  Cardiovasc Diabetol, 2019, 18(1): 162. DOI: 10.1186/s12933-019-0969-z.

40..Galindo RJ, Fayfman M, Umpierrez GE. Perioperative management of hyperglycemia and diabetes in cardiac surgery patients[J]. Endocrinol Metab Clin North Am, 2018, 47(1): 203-222. DOI: 10.1016/j.ecl.2017.10.005.

41..刘赫, 李野. 体外循环心脏手术围术期高血糖对预后的影响[J]. 哈尔滨医科大学学报, 2017, 51(2): 164-167. [Liu H, Li Y. Effect of perioperative hyperglycemia on the prognosis of cardiopulmonary bypass cardiosur-gery[J]. Journal of Harbin Medical University, 2017, 51(2): 164-167.] DOI: 10.3969/j.issn.1000-1905.2017.02.017.

42..王前伟, 苏丕雄, 顾松, 等. 入院hba1c与冠状动脉旁路移植术后血糖波动及不良事件的相关性研究[J]. 中国胸心血管外科临床杂志, 2019, 26(10): 963-967. [Wang QW, Su PX, Gu S, et al. Correlation between HbA1c on admission and blood glucose fluctuations and adverse events after coronary artery bypass grafting in non-diabetic patients[J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2019, 26(10): 963-967.] DOI: 10.7507/1007-4848.201901012.

43..马麟麟. 中国器官移植受者血脂管理指南(2016版)[J]. 器官移植, 2016, 7(4): 243-254. [Ma QL. Guidelines for lipid Management of organ transplant recipients in China (2016)[J]. Organ Transplantation, 2016, 7(4): 243-254.] DOI: 10.3969/j.issn.1674-7445.2016.04.001.

44..Heeney SA, Tjugum SL, Corkish ME, et al. Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus[J]. Clin Transplant, 2019, 33(1): e13454. DOI: 10.1111/ctr.13454.

45..Wang KL, Liu CJ, Chao TF, et al. Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy[J]. Am J Cardiol, 2014, 113(4): 631-636. DOI: 10.1016/j.amjcard.2013.10.043.

46..Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative me-ta-analysis of randomised statin trials[J]. Lancet, 2010, 375(9716): 735-742. DOI: 10.1016/S0140-6736(09)61965-6.

47..Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes[J]. J Am Coll Cardiol, 2013, 61(2): 148-152. DOI: 10.1016/j.jacc.2012.09.042.

48..Jennings DL, Sultan L, Mingov J, et al. Pcsk9 inhibitors safely and effectively lower ldl after heart trans-plantation: a systematic review and meta-analysis[J]. Heart Fail Rev, 2022, 28(1): 149-156. DOI: 10.1007/s10741-022-10255-5.

49..Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic out-comes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the odyssey outcomes randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(8): 618-628. DOI: 10.1016/S2213-8587(19)30158-5.

50..石炳毅, 贾晓伟, 李宁. 中国移植后糖尿病诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(1): 1-9. [Shi BY, Jia XW, Li N. Diagnosis and treatment specifications technical specification for diagnosis and treatment of post transplantation diabetes mellitus in China (2019 edition) [J]. Organ Transplantation, 2019, 10(1): 1-9.] DOI: 10.3969/j.issn.1674-7445.2019.01.001.

51..Chowdhury TA, Wahba M, Mallik R, et al. Association of British clinical diabetologists and renal asso-ciation guidelines on the detection and management of diabetes post solid organ transplantation[J]. Diabet Med, 2021, 38(6): e14523. DOI: 10.1111/dme.14523.